HMGN2P20

Across TCGA pan-cancer cohorts, HMGN2P20 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of HMGN2P20’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where HMGN2P20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HMGN2P20 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

STAD, HNSC, and THCA are the cancer types where HMGN2P20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HMGN2P20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	All	II,III,IV	+0.459	.002	6	view →
HNSC	Male	III,IV	+0.170	.022	6	view →
THCA	All	All	−0.140	.002	5	view →
BRCA	All	All	+0.157	.021	4	view →
LUSC	All	All	−0.100	.010	3	view →
KIRP	All	All	−0.074	.035	3	view →
LUAD	All	IV	+0.425	.006	2	view →
KICH	All	All	−0.060	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

HMGN2P20–STAD

Open the STAD breakdown →